Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Presentation Material for Information Meeting (Q1/FY2021)

07/29/2021 | 11:09pm EDT

Q1/FY2021 FINANCIAL RESULTS

ENDED JUNE 30, 2021

Naoki Okamura

Executive Vice President,

Chief Strategy Officer and Chief Financial Officer

Astellas Pharma Inc.

July 30, 2021

CAUTIONARY STATEMENT REGARDING FORWARD-

2

LOOKING INFORMATION

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

AGENDA

3

  1. Q1/FY2021 Consolidated Financial Results FY2021 Revised Forecasts
  1. Initiatives for Sustainable Growth

Q1/FY2021 FINANCIAL RESULTS

4

(billion yen)

Q1/FY20

Q1/FY21

Change

Change

FY21

Progress

FX impact

(%)

FCST

Revenue

307.0

326.1

+19.2

+6.2%

1,323.0

24.7%

+13.6 bil. yen

Cost of sales

59.7

62.2

+2.6

+4.3%

% of revenue

19.4%

19.1%

-0.4 ppt

SG&A expenses

120.8

137.1

+16.3

+13.5%

541.0

25.3%

US XTANDI co-pro fee

31.5

34.5

+3.0

+9.4%

SG&A excl. the above

89.3

102.6

+13.4

+15.0%

R&D expenses

57.3

58.3

+1.0

+1.8%

242.0

24.1%

Amortisation of

5.9

6.0

+0.1

+1.8%

intangible assets

Core operating profit

63.4

62.8

-0.6

-0.9%

270.0

23.3%

+6.1 bil. yen

Other income

2.2

0.4

-1.8

-

Other expense

4.8

27.1

+22.3

-

Operating profit

60.8

36.1

-24.7

-40.7%

265.0

13.6%

Profit before tax

60.2

35.8

-24.4

-40.5%

263.0

13.6%

Profit

50.4

30.7

-19.7

-39.1%

209.0

14.7%

Q1/FY2021 FINANCIAL RESULTS: OVERVIEW

5

Revenue increased, Core OP was the same level as previous fiscal year and in line with assumptions of full-year forecast

  • Sales of XTANDI and Strategic products* increased as expected, offsetting sales decrease due to the transfer of mature products
  • SG&A spending is slightly ahead of full-year forecast R&D expenses are on track

Full basis: OP and Profit were behind full-year forecast

  • Booked impairment losses, not included in full-year forecast: Termination of development for ASP0892 and bleselumab

* XOSPATA, PADCEV, Evrenzo

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Astellas Pharma Inc. published this content on 30 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 03:08:05 UTC.


© Publicnow 2021
All news about ASTELLAS PHARMA INC.
09/09ASTELLAS PHARMA : Updates “Contact for Potential Acquisition of ' R&D Prog..
PU
09/02ASTELLAS PHARMA : Nitto, and M. Heart Partnering for ECG testing service
PU
09/01Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X..
CI
08/31ASTELLAS PHARMA : Announces Personnel Changes
PU
08/30ASTELLAS PHARMA : Launches its Corporate Website's New Modalities~Approac..
PU
08/20SECTOR UPDATE : Health Care Stocks Mixed Premarket Friday
MT
08/20FIBROGEN : Receives $120 Million Milestone Payment With Approval of Evrenzo in E..
MT
08/20ASTELLAS PHARMA : Receives European Commission Approval for First-in-Class EVREN..
PU
08/19ASTELLAS PHARMA : Receives European Commission Approval for First-in-Class EVREN..
AQ
08/19ASTELLAS PHARMA : Receives EC Approval for First-inClass EVRENZO (roxadustat) fo..
PU
More news
Financials
Sales 2022 1 325 B 12 073 M 12 073 M
Net income 2022 196 B 1 784 M 1 784 M
Net cash 2022 478 B 4 352 M 4 352 M
P/E ratio 2022 17,7x
Yield 2022 2,66%
Capitalization 3 488 B 31 807 M 31 786 M
EV / Sales 2022 2,27x
EV / Sales 2023 1,91x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 882,50 JPY
Average target price 2 451,54 JPY
Spread / Average Target 30,2%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura Representative Director, VP & Head-Finance
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.18.10%31 508
JOHNSON & JOHNSON5.11%435 465
ROCHE HOLDING AG11.23%327 497
PFIZER, INC.21.46%251 011
NOVO NORDISK A/S49.16%231 607
ELI LILLY AND COMPANY38.43%211 895